辅助化疗可能改善淋巴结阳性管腔A型乳腺癌

北京中科医院怎么样 http://m.39.net/news/a_5218643.html

GenetMolRes.;14(3):-73.

AdjuvantchemotherapymayimprovesurvivalofpatientswithluminalAbreastcancerandpositivelymphnodes.

HanY,LiQ,XuBH,ZhangP,YuanP,WangJY,MaF,CaiRG,FanY.

DepartmentofMedicalOncology,CancerHospital,ChineseAcademyofMedicalSciences,PekingUnionMedicalCollege,ChaoyangDistrict,Beijing,China.

ThestudyexaminedtheclinicopathologicalcharacteristicsandtreatmentoptionsinpatientswithluminalAbreastcancer.ThisretrospectivecohortincludedpatientswithluminalAbreastcancertreatedbetweenJanuaryandJune.Patientsweredividedintofoursubgroupsaccordingtolymphnodestatus.Prognosticfactorsand5-yearoverallsurvival(OS)anddisease-freesurvival(DFS)ofpatientswereanalyzed.Themediandurationoffollow-upwas67months.MultivariateCox-regressionanalysisrevealedthatpatientsintheLN2andLN3subgroupshadahigherriskofrecurrenceanddeaththanpatientsintheLN0subgroup(LN2:HR=2.2forDFSandHR=2.1forOS;LN3:HR=4.7forDFSandHR=4.7forOS).IntheLN2subgroup,therewasatrendtowardsreducedriskofrecurrenceanddeathforpatientsreceivingadjuvantchemotherapyplusendocrinetherapy,althoughthisdifferencedidnotreachstatisticalsignificance.IntheLN0andLN1subgroups,therewasatrendtowardsanincreasedriskofdeathinpatientsreceivingchemotherapy.AlthoughlymphnodestatusremainsoneofthemostimportantindependentprognosticpredictorsforluminalAbreastcancer,inpatientswith0-3positivelymphnodesendocrinetherapycanbeconsideredsufficient.However,patientswith≥4positivelymphnodes,andespeciallyinthosewith≥10,shouldreceivechemotherapy.

PMID:

DOI:10./.July.31.4

PDF↓

预览时标签不可点收录于话题#个上一篇下一篇